Travere Therapeutics (TVTX) Q2 2026 earnings summary

Executive summary

• FILSPARI achieved record U.S. net sales of $141.1M in Q2 2026, up 96% year-over-year, driven by strong demand in both IgA nephropathy and a successful FSGS launch, with over 2,000 new patient start forms.

• FILSPARI is now approved and commercially available for both IgA nephropathy and FSGS, establishing itself as a foundational nephroprotective therapy with significant market runway and less than 10% market penetration.

• Advanced pipeline with pegtibatinase in pivotal Phase 3 HARMONY Study for homocystinuria, topline data expected in 2H 2027, and added civorebrutinib through an exclusive licensing agreement.

• Civorebrutinib, a next-generation BTK inhibitor, demonstrated rapid and sustained biomarker reductions and favorable safety in pMN, supporting further development in rare kidney diseases.

Financial highlights

• Total U.S. net product sales reached $161.4M in Q2 2026, up strongly year-over-year and sequentially.

• FILSPARI U.S. net product sales grew 96% year-over-year to $141.1M.

• Total revenue for the quarter was $169.6M, including $8.2M in licensing collaboration revenue.

• Cash, equivalents, and marketable securities were $489.2M as of June 30, 2026.

• GAAP R&D and SG&A expenses totaled $156.4M, including $22.2M in non-cash expenses.

Outlook and guidance

• Expect continued FILSPARI revenue growth in both FSGS and IgA nephropathy, supported by label expansion and evolving treatment guidelines.

• Full-year gross net discounts for FILSPARI anticipated in the mid-20% range.

• Topline results from the HARMONY Phase 3 study for pegtibatinase expected in 2H 2027.

• Plans to initiate a Phase 4 study for FILSPARI in FSGS patients of African ancestry in 2H 2026.

• Peak annual FILSPARI sales potential estimated at over $3 billion.